Core Insights - Illumina's CEO Jacob Thaysen highlighted the company's growth opportunities in the China market during the JPMorgan Health-Care Conference [1] - The discussion also touched on the potential for Illumina to be acquired, indicating strategic considerations for the company's future [1] Group 1: Market Opportunities - The China market presents significant growth potential for Illumina, suggesting a focus on expanding its presence in this region [1] - The company is exploring various strategies to capitalize on the increasing demand for genomic sequencing in China [1] Group 2: Acquisition Possibilities - Thaysen mentioned the possibility of Illumina being acquired, which reflects the company's strategic positioning and interest from potential buyers [1] - This consideration may influence investor sentiment and market dynamics surrounding Illumina [1]

Core Insights - Illumina is experiencing a return to growth, with a focus on its fourth quarter 2025 results [3] - The company emphasizes its differentiated ecosystem and workflow, which positions it well for continued growth, particularly in clinical markets [3] - Strategic positioning and disciplined execution are highlighted as key factors for profitable growth moving forward [3] Company Overview - Illumina is the market leader in next-generation sequencing, offering highly innovative products and maintaining the largest and most diverse installed base in the industry [4] - The company serves an installed base of over 20,000 instruments globally, spanning clinical, research, and applied markets [4] - This extensive scale allows Illumina to reach across the entire lifecycle from early discovery to routine clinical use [4]

Summary of Illumina's Presentation at J.P. Morgan Healthcare Conference Company Overview - **Company**: Illumina - **Industry**: Next-generation sequencing (NGS) - **Market Position**: Market leader with over 20,000 instruments globally across clinical, research, and applied markets [3][4] Key Financial Highlights - **Q4 2025 Revenue Growth**: Grew 4% on a constant currency basis and 7% excluding China [4] - **Earnings Per Share (EPS)**: Q4 EPS ranged from $1.27 to $1.30, leading to a full-year EPS of approximately $4.76 to $4.79, representing over 15% growth [4][6] - **Clinical Market Contribution**: Clinical markets accounted for roughly 60% of consumables revenue, driving significant growth [12][33] Product and Market Dynamics - **NovaSeq X Series**: Launched in 2023, it doubled customers' sequencing capacity and accounted for approximately 80% of high-throughput gigabases shipped by year-end 2025 [3][5] - **Consumables Growth**: Achieved 20% consumables growth ex-China in Q4, driven by strong clinical utilization [6][26] - **Transition to NovaSeq X**: The transition is expected to continue, with clinical customers increasingly adopting larger panels and deeper sequencing [40][42] Strategic Initiatives - **BioInsights Launch**: Aimed at enhancing clinical interpretation and expanding data utilization in drug discovery [11][16] - **Multi-Omics Expansion**: New product offerings in multi-omics, including single-cell solutions and proteomics, are designed to scale research programs and improve insights [15][54] - **AI Integration**: Leveraging AI to enhance drug discovery and biological insights through large-scale data analysis [16][56] Market Outlook - **Clinical Market Growth**: Anticipated to remain a key growth driver, with expectations of continued demand for NGS tests in oncology, genetic diseases, and reproductive health [5][33] - **Research Market Sentiment**: While there is optimism for the clinical market, the academic research environment is expected to remain muted in the near term [33] Competitive Landscape - **Technological Advantages**: Illumina emphasizes the importance of providing comprehensive solutions beyond just hardware, focusing on workflow optimization and customer success [45][46] - **Resilience in Challenges**: Despite geopolitical challenges in 2025, Illumina demonstrated resilience and continued to grow its bottom line [32][33] Capital Allocation and Shareholder Returns - **Cash Flow Generation**: Approximately $1 billion per year in strong and durable cash flow, with a free cash flow conversion of about 140% [17] - **Share Repurchases**: Returned $740 million to shareholders via share repurchases in June 2025 [18] Conclusion - **Future Focus**: Illumina aims to continue innovation, execute with discipline, and deploy capital thoughtfully to drive long-term value creation and maximize shareholder value [18]

44th Annual J.P. Morgan Healthcare Conference Jacob Thaysen, PhD Chief Executive Officer January 13, 2026 © 2026 Illumina, Inc. All rights reserved. © 2026 Illumina, Inc. All rights reserved. Cautionary Notes On Forward Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: J.P. Morgan Healthc ...

Core Insights - Illumina has launched a new dataset that maps genetic changes aimed at enhancing drug discovery through the use of artificial intelligence [1] Company Summary - The introduction of the dataset is expected to facilitate the acceleration of drug discovery processes [1]

Core Insights - Illumina has launched the world's largest genome-wide genetic perturbation dataset, the Illumina Billion Cell Atlas, aimed at accelerating drug discovery through AI across the pharmaceutical ecosystem [1][2] - The Atlas is part of a larger initiative to create a 5 billion cell atlas over three years, representing the most comprehensive map of human disease biology to date [1][11] Group 1: Collaboration and Partnerships - The Atlas is being developed in collaboration with founding partners AstraZeneca, Merck, and Eli Lilly, focusing on drug target validation and training advanced AI models [2][3] - Merck plans to utilize the Atlas to enhance precision medicine approaches in their drug discovery pipelines, leveraging AI/ML models to improve disease prediction [3][4] Group 2: Technological Advancements - The Atlas will capture responses of 1 billion individual cells to genetic changes via CRISPR across over 200 disease-relevant cell lines, including those related to immune disorders, cancer, and rare genetic diseases [5] - The Illumina Single Cell 3' RNA prep platform enables the capture of millions of individual cells in a single experiment, generating 20 petabytes of single-cell transcriptomic data annually [9] Group 3: Research and Development Impact - The Atlas will facilitate the characterization of drug and disease mechanisms, exploration of new indications, and validation of candidate targets from human genetics [6] - The initiative aims to translate genetic information into a clearer understanding of disease mechanisms, thereby enhancing drug development decisions [7] Group 4: Future Prospects - Illumina's BioInsight business is set to provide foundational technologies and datasets for the next generation of drug discovery and AI in pharmaceuticals [10] - The company is actively expanding multi-billion cell atlases over time, building on previous initiatives to create a comprehensive single-cell resource [11]

Revenue Performance - Revenue for Q4 2025 was approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% on a constant currency basis) [7] - Ex-China revenue for Q4 2025 was approximately $1.100 billion, up 7% from Q4 2024 [7] - Full fiscal year 2025 revenue was approximately $4.34 billion, flat compared to 2024 [7] - Ex-China revenue for fiscal year 2025 was approximately $4.10 billion, up 2% from 2024 [7] - Constant currency revenue for Q4 2025, excluding hedge effects, was approximately $1.159 billion, a 5% increase from Q4 2024 [14] Earnings Per Share (EPS) - GAAP diluted EPS for Q4 2025 is projected to be between $2.14 and $2.17, while non-GAAP diluted EPS is expected to be between $1.27 and $1.30 [7] - GAAP diluted EPS for fiscal year 2025 is projected to be between $5.42 and $5.45, with non-GAAP diluted EPS expected between $4.76 and $4.79 [7] Business Acquisition and Integration - The company is in the process of acquiring SomaLogic, Inc., which may impact future financial results [9] - The company anticipates challenges in integrating the SomaLogic Business and managing partner relationships in the proteomics market [9] Forward-Looking Guidance - Forward-looking guidance is provided on a non-GAAP basis, with uncertainties regarding future financial measures due to various factors [8]

Core Insights - Illumina, Inc. announced preliminary financial results for Q4 and fiscal year 2025 ahead of the J.P. Morgan Healthcare Conference [1] Preliminary Fourth Quarter 2025 Results - Revenue for Q4 2025 is approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% increase on a constant currency basis) [7] - Ex-China revenue for Q4 2025 is approximately $1.100 billion, up 7% from Q4 2024 [7] - GAAP diluted EPS is projected to be between $2.14 and $2.17, while non-GAAP diluted EPS is expected to be between $1.27 and $1.30 [7] Preliminary Fiscal Year 2025 Results - Total revenue for fiscal year 2025 is approximately $4.34 billion, flat compared to 2024 (constant currency basis) [7] - Ex-China revenue for fiscal year 2025 is approximately $4.10 billion, up 2% from 2024 [7] - GAAP diluted EPS for the fiscal year is projected to be between $5.42 and $5.45, while non-GAAP diluted EPS is expected to be between $4.76 and $4.79 [7] Non-GAAP Financial Measures - The company reports non-GAAP results to provide a clearer view of operating performance, excluding certain charges such as amortization of acquired intangible assets and other adjustments [3][4] - Non-GAAP diluted EPS is a key metric used by the board of directors to assess management performance and compensation [3][14] Forward-Looking Guidance - The company provides forward-looking guidance on a non-GAAP basis, including revenue growth rates, but cannot reconcile these to GAAP measures due to uncertainties [5][6] About Illumina - Illumina focuses on improving human health through genomic technologies, serving various markets including life sciences, oncology, and agriculture [9]

Core Viewpoint - Illumina, Inc. will announce its fourth quarter and full year 2025 results on February 5, 2026, after market close [1] Group 1: Conference Call Details - The conference call will take place at 1:30 pm Pacific Time (4:30 pm Eastern Time) on February 5, 2026 [2] - Interested parties can access the live webcast through Illumina's Investor Info section or via a direct link [2] - Participants are advised to join at least ten minutes before the scheduled start time to ensure timely connection [2] Group 2: Replay Information - A replay of the conference call will be available on Illumina's website for at least 30 days following the event [3] Group 3: Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on improving human health through genomic advancements [4] - The company's products serve various markets, including life sciences, oncology, reproductive health, and agriculture [4] - Illumina emphasizes innovation to maintain its leadership position in the industry [4]

Core Insights - Illumina, Inc. has launched Illumina Connected Multiomics, a cloud-based platform for analyzing and visualizing multiomic and multimodal biological data at scale, which was developed with input from 40 early access users [1][5] - The launch is expected to enhance the user experience across Illumina's software portfolio and is aimed at advancing precision health discovery and drug development [2][3] Company Performance - Following the announcement of Connected Multiomics, Illumina's shares increased by 4.1%, closing at $147.11, indicating a positive market reaction [3][9] - Illumina currently has a market capitalization of $21.56 billion and an earnings yield of 3.6%, which is significantly better than the industry's -16.4% yield [4] Product Features - Connected Multiomics can aggregate thousands of multiomic samples from both Illumina and third-party assays, providing reproducible results and interactive visualizations in a single cloud-based environment [5] - The platform includes AI-enabled variant interpretation to enhance the analysis process by identifying biologically meaningful signals earlier [5][6] Industry Outlook - The global multiomics market was valued at $2.7 billion in 2024 and is projected to grow at a CAGR of 15.3% by 2033, driven by increasing demand for single-cell multiomics and advancements in omics technologies [10] - Key components such as genomics, proteomics, metabolomics, and transcriptomics are seeing increased adoption in healthcare applications, which bodes well for Illumina's growth [10] Stock Performance - Over the past three months, Illumina's shares have risen by 48.5%, outperforming the industry growth of 12.7% [12]